Show simple item record

dc.contributor.authorSánchez Maldonado, José Manuel
dc.contributor.authorCáliz Cáliz, Antonio Rafael 
dc.contributor.authorLópez Nevot, Miguel Ángel 
dc.contributor.authorCabrera Serrano, Antonio José
dc.contributor.authorMoñiz Díez, Ana
dc.contributor.authorFerrer Gamarra, Miguel Ángel 
dc.contributor.authorJurado Chacón, Manuel 
dc.contributor.authorSáinz Pérez, Juan 
dc.date.accessioned2021-12-10T09:42:41Z
dc.date.available2021-12-10T09:42:41Z
dc.date.issued2021-10-27
dc.identifier.citationSánchez-Maldonado JM... [et al.] (2021) Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. Front. Immunol. 12:672255. doi: [10.3389/fimmu.2021.672255]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/71973
dc.descriptionThis study was supported by grants PI17/02276 and PI20/01845 from Fondo de Investigaciones Sanitarias (Madrid, Spain) and by intramural funds of GENYO and FIBAO foundation (Granada, Spain). This study was also supported by the Novo Nordisk Fonden (NNF15OC0016932, VA) and Knud og Edith Eriksens Mindefond (VA) and Gigtforeningen (A2037, A3570, VA). JS and KB-K were supported by the grant No. 2016/21/B/NZ5/01901 from the National Science Centre (Poland). MGN was supported by a Spinoza grant from the Netherlands Organization for Scientific Research. YL was supported by an ERC Starting Grant (948207) and the Radboud University Medical Centre Hypatia Grant (2018) for Scientific Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.description.abstractWe aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected markers and evaluated their association with response to TNFi after 6 months of treatment according to the change in disease activity score 28 (DDAS28). Next, we confirmed the most interesting results through meta-analysis of our data with those from the DREAM cohort that included 706 RA patients treated with TNFi. The meta-analysis of the discovery cohort and DREAM registry including 2067 RA patients revealed an overall association of the LINC02549rs7767069 SNP with a lower improvement in DAS28 that remained significant after correction for multiple testing (perallele ORMeta=0.83, PMeta=0.000077; PHet=0.61). In addition, we found that each copy of the LRRC55rs717117G allele was significantly associated with lower improvement in DAS28 in rheumatoid factor (RF)-positive patients (per-allele ORMeta=0.67, P=0.00058; PHet=0.06) whereas an opposite but not significant effect was detected in RF-negative subjects (per-allele ORMeta=1.38, P=0.10; PHet=0.45; PInteraction=0.00028). Interestingly, although the identified associations did not survive multiple testing correction, the metaanalysis also showed overall and RF-specific associations for the MAFBrs6071980 and CNTN5rs1813443 SNPs with decreased changes in DAS28 (per-allele ORMeta_rs6071980 = 0.85, P=0.0059; PHet=0.63 and ORMeta_rs1813443_RF+=0.81, P=0.0059; PHet=0.69 and ORMeta_rs1813443_RF-=1.00, P=0.99; PHet=0.12; PInteraction=0.032). Mechanistically, we found that subjects carrying the LINC02549rs7767069T allele had significantly increased numbers of CD45RO+CD45RA+ T cells (P=0.000025) whereas carriers of the LINC02549rs7767069T/T genotype showed significantly increased levels of soluble scavengers CD5 and CD6 in serum (P=0.00037 and P=0.00041). In addition, carriers of the LRRC55rs717117G allele showed decreased production of IL6 after stimulation of PBMCs with B burgdorferi and E coli bacteria (P=0.00046 and P=0.00044), which suggested a reduced IL6-mediated anti-inflammatory effect of this marker to worsen the response to TNFi. In conclusion, this study confirmed the influence of the LINC02549 and LRRC55 loci to determine the response to TNFi in RA patients and suggested a weak effect of the MAFB and CNTN5 loci that need to be further investigated.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III PI17/02276 PI20/01845es_ES
dc.description.sponsorshipGENYO foundation (Granada, Spain)es_ES
dc.description.sponsorshipFIBAO foundation (Granada, Spain)es_ES
dc.description.sponsorshipNovo Nordisk Foundation NNF15OC0016932es_ES
dc.description.sponsorshipKnud og Edith Eriksens Mindefondes_ES
dc.description.sponsorshipGigtforeningen A2037 A3570es_ES
dc.description.sponsorshipNational Science Centre, Poland 2016/21/B/NZ5/01901es_ES
dc.description.sponsorshipSpinoza grant from the Netherlands Organization for Scientific Researches_ES
dc.description.sponsorshipEuropean Research Council (ERC) European Commission 948207es_ES
dc.description.sponsorshipRadboud University Medical Centre Hypatia Grant (2018)es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Research Foundationes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectGWASes_ES
dc.subjectGenetic variantes_ES
dc.subjectRheumatoid arthritis es_ES
dc.subjectDrug responsees_ES
dc.subjectTNF inhibitorses_ES
dc.titleValidation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohortses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/948207es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3389/fimmu.2021.672255
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España